Want to see TXMD full AI Analyst Report?
TherapeuticsMD (TXMD) AI Stock Analysis
TherapeuticsMD
(NASDAQ:TXMD)
TXMD scores below average, driven primarily by weak fundamentals: TTM revenue of only $3.3M, continued operating losses, and a business that has effectively wound down to a royalty-collection vehicle. Offsetting strengths include a de-levered balance sheet ($5.6M debt versus $27.1M equity), positive operating cash flow of $3.1M TTM, and $9.2M of cash. Valuation provides no cushion given negative earnings and no dividend. Technicals are the brightest spot, with price above all key moving averages, though an RSI above 74 signals the move is overbought. The pending strategic alternatives review introduces meaningful uncertainty — it could unlock value through a transaction, but declining royalty revenue and rising expenses in the interim keep the risk profile elevated.
TherapeuticsMD (TXMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $20.83M
- Dividend Yield
- ―
- Average Volume (3M)
- 23.67K
- Price to Earnings (P/E)
- -95.7
- Beta (1Y)
- 1.08
- Revenue Growth
- 27.78%
- EPS Growth
- 52.88%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
TherapeuticsMD Business Overview & Revenue Model
Company Description
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradi...
How the Company Makes Money
TherapeuticsMD has generated revenue primarily through out-licensing/partnering arrangements for its product portfolio rather than through building a fully integrated, long-term direct commercial sales model. Under these types of agreements, the comp...
TherapeuticsMD Financial Statement Overview
Summary
Financials reflect a micro-cap in the final stage of a wind-down. The income statement is the weakest link (score 25): TTM revenue of just $3.3M versus $70M in 2022, with operating margins deeply negative (-142% EBIT margin), though losses have narrowed sharply to -$217K TTM. The balance sheet is the strongest element (score 55), with equity restored to $27.1M from -$93.6M in 2021, debt cut from $197.7M to $5.6M, and a conservative 0.20 debt-to-equity ratio. Cash flow (score 48) has flipped positive at $3.1M TTM after massive historical outflows. The de-risking and improving trajectory are genuine positives, but the tiny revenue base, lack of operating profitability, and shrinking asset base cap the score well below average.
Income Statement
25NegativeBalance Sheet
55NeutralCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.27M | 3.02M | 1.76M | 1.30M | 69.96M | 2.57M |
| Gross Profit | 2.94M | 3.02M | 1.76M | 1.30M | 68.57M | 1.17M |
| EBITDA | -3.96M | -3.02M | -4.33M | -7.60M | 11.86M | -78.84M |
| Net Income | -217.00K | -569.00K | -2.18M | -10.28M | 112.00M | -172.41M |
Balance Sheet | ||||||
| Total Assets | 37.53M | 37.66M | 38.82M | 43.31M | 90.46M | 169.47M |
| Cash, Cash Equivalents and Short-Term Investments | 9.19M | 7.48M | 5.06M | 4.33M | 38.07M | 64.91M |
| Total Debt | 5.56M | 6.10M | 7.17M | 8.01M | 8.76M | 197.69M |
| Total Liabilities | 10.40M | 10.78M | 11.45M | 14.02M | 55.31M | 263.09M |
| Stockholders Equity | 27.13M | 26.88M | 27.37M | 29.29M | 35.14M | -93.62M |
Cash Flow | ||||||
| Free Cash Flow | 3.12M | 2.42M | 732.00K | 0 | -4.43M | -147.84M |
| Operating Cash Flow | 3.12M | 2.42M | 732.00K | -48.14M | -4.08M | -147.81M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 223.48M | -2.22M |
| Financing Cash Flow | 0 | 0 | 0 | 3.15M | -235.21M | 134.67M |
TherapeuticsMD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Negative. The current price of 1.80 is below the 20-day moving average (MA) of 1.91, below the 50-day MA of 2.05, and below the 200-day MA of 2.12, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 33.34 is Neutral, neither overbought nor oversold. The STOCH value of 25.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TXMD.
TherapeuticsMD Risk Analysis
TherapeuticsMD disclosed 49 risk factors in its most recent earnings report. TherapeuticsMD reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksTherapeuticsMD Peers Comparison
Overall Rating
AYTU62Neutral- TXMD47Neutral
PRPH41Neutral
RDHL41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AYTU | 62Neutral | $20.98M | -1.41 | -52.89% | ― | -13.27% | 27.11% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TXMD | 47Neutral | $20.83M | -95.74 | -0.80% | ― | 27.78% | 52.88% |
| PRPH | 41Neutral | $139.52K | -0.00 | -1358.66% | ― | ― | ― |
| RDHL | 41Neutral | $3.45M | -2.85 | 206.75% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TXMD | Therapeuticsmd Inc | 1.80 | 0.65 | 56.52% | |
| PRPH | Prophase Labs | 0.01 | -3.24 | -99.69% | |
| RDHL | RedHill Biopharma Ltd | 0.39 | -0.88 | -69.53% | |
| AYTU | Aytu BioScience | 1.93 | -0.28 | -12.67% | |
| GELS | Gelteq Limited | 0.49 | -0.63 | -56.25% |
TherapeuticsMD Corporate Events
TherapeuticsMD Q2 Results and Strategic Alternatives Review
NegativeOn August 11, 2026, TherapeuticsMD reported second quarter 2026 results for the period ended June 30, highlighting net income from continuing operations of $164 thousand, down from $545 thousand a year earlier. License revenue slipped to $869 thousan...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 26, 2026